IDEAYA Biosciences (IDYA) 2025 Conference September 03, 2025 09:10 AM ET Company ParticipantsJoshua Bleharski - CFOLi Watsek - DirectorYujiro Hata - Co-Founder, President, CEO & DirectorLi WatsekGood morning, everyone. Welcome to the first day of our Kenter Healthcare Conference. My name is Lee Waltzeck, a biotech analyst here at Kenter. Today, I'm very pleased to have the IDEAYA team with us today, Yujiro and Josh. Thank you very much for being here. By the way, congratulations on the Sevier deal yesterday ...

enGene Holdings (ENGN) FY 2025 Conference September 03, 2025 08:45 AM ET Company ParticipantsRon Cooper - CEO & DirectorConference Call ParticipantsYanan Zhu - Senior Analyst - Biotechnology Equity ResearchRon CooperLate, in terms of helping the profile of detalimogene voraplasmid. Now, those protocol amendments were effectively implemented near the end of last year. As we were enrolling patients, we would like to have a reasonable cohort, reasonable size cohort of patients, at least three to six months' da ...

enGene Holdings (ENGN) FY 2025 Conference September 03, 2025 08:45 AM ET Speaker0Late, in terms of helping the profile of detalimogene voraplasmid. Now, those protocol amendments were effectively implemented near the end of last year. As we were enrolling patients, we would like to have a reasonable cohort, reasonable size cohort of patients, at least three to six months' data where you could see the impact of those changes. That's what we're really waiting for. This morning, we shared our guidance that in ...

Enanta Pharmaceuticals (ENTA) 2025 Conference September 03, 2025 08:35 AM ET Speaker2Welcome to the Cantor Global Healthcare Conference. I'm Pete Stavropoulos, a biotech analyst with Cantor. With us, we have Enanta Pharmaceuticals, Inc., a company that's developing drugs in viral antivirals and immunology indications. I'm pleased to introduce Jay R. Luly, President and Chief Executive Officer, and Tara L. Kieffer, Chief Product Strategy Officer. We'd like to welcome you, but also my condolences for Paul.Spe ...

Wave Life Sciences (WVE) Update / Briefing September 03, 2025 08:30 AM ET Company ParticipantsPaul Bolno - President, CEO & DirectorChris Wright - Chief Medical OfficerJoseph Schwartz - Senior MD - Rare DiseasesErik Ingelsson - Chief Scientific OfficerBenjamin Paluch - Equity Research Senior Associate - BiotechYun Zhong - SVP - Equity ResearchCatherine Novack - Director - HealthcareSteve Seedhouse - Biotechnology Equity ResearchAngela Qian - Vice PresidentConference Call ParticipantsJoon Lee - MD & Senior B ...

Core Viewpoint - Ernexa Therapeutics is an innovator in developing novel cell therapies for advanced cancer and autoimmune diseases, and will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1][5]. Company Overview - Ernexa Therapeutics (NASDAQ: ERNA) focuses on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) for scalable, off-the-shelf treatments without the need for patient-specific cell harvesting [6]. - The company is advancing two lead programs: ERNA-101, aimed at stimulating immune response against ovarian cancer, and ERNA-201, which targets inflammation to treat autoimmune diseases [4][7]. Presentation Details - Sanjeev Luther, President and CEO, along with Robert Pierce, M.D., Chief Scientific Officer, will provide an overview of the company's business, recent milestones, and pipeline during the conference [3]. - The presentation will emphasize Ernexa's proprietary iMSC platform, which enables scalable cell therapies for cancer and autoimmune diseases [3]. Future Outlook - The company aims to advance ERNA-101 toward clinical trials by 2026, highlighting its potential to change treatment paradigms for cancer and autoimmune diseases [5].

Company Overview - Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on creating new medicines for pain and fatigue-related disorders [3] - The company is publicly traded on Nasdaq under the ticker DWTX [3] Upcoming Events - Dogwood Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025 [1] - CEO Greg Duncan will engage in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright on September 5, 2025, with the presentation available on-demand [2] Research and Development - The company has a research pipeline that includes a non-opioid analgesic program and an antiviral program [3] - The lead candidate in the analgesic program is Halneuron, which targets voltage-gated sodium channels to reduce pain transmission, showing efficacy in treating cancer-related pain and chronic chemotherapy-induced neuropathic pain [3] - Interim data from the ongoing Phase 2 study of Halneuron for chronic chemotherapy-induced neuropathic pain is expected in Q4 2025 [3] Antiviral Program - Dogwood's antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib [4] - IMC-1 is advancing towards Phase 3 development for fibromyalgia, while IMC-2 has shown success in reducing fatigue associated with Long-COVID in clinical trials [4] - The company has reached an agreement with the FDA to use fatigue reduction as the primary endpoint for future IMC-2 research related to Long-COVID [4]

Core Insights - Adagene Inc. has appointed Dr. Axel Hoos as Executive Advisor, enhancing its leadership in immuno-oncology [1][2] - The company is advancing innovative antibody therapies targeting CTLA-4, aiming to improve efficacy and reduce toxicity in cancer treatment [2][6] - Dr. Hoos brings extensive experience in immuno-oncology, having previously led the development of YERVOY, the first FDA-approved immune checkpoint inhibitor [2][3][4] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [5] - The company utilizes its SAFEbody precision masking technology to address safety and tolerability challenges in antibody therapeutics [6] Pipeline and Technology - Adagene's lead clinical program, ADG126, is a masked anti-CTLA-4 SAFEbody currently in phase 1b/2 studies, particularly targeting Metastatic Microsatellite-stable Colorectal Cancer [7] - The SAFEbody platform allows for tumor-specific targeting while minimizing off-tumor toxicity, enhancing the therapeutic window for antibody treatments [6][7]

Editas Medicine (EDIT) FY 2025 Conference September 03, 2025 08:00 AM ET Company ParticipantsDana Sheehan - Associate Director - Corporate CommunicationsGilmore O’Neill - Director, President & CEOLinda Burkly - EVP & Chief Scientific OfficerAlec Stranahan - VP - Equity ResearchBill Maughan - MD, Equity Research - BiotechnologyJonathan Miller - MD - Biotech & Pharma Equity ResearchSoumit Roy - MD - HealthcareTony Deng - VP - Biotechnology Equity ResearchConference Call ParticipantsJack Allen - Senior Researc ...

Editas Medicine (EDIT) FY 2025 Conference September 03, 2025 08:00 AM ET Speaker0Our lead development candidate, Edit 401. This webinar is being recorded and can be accessed in the future through this same link or through the Investors section of the company's website. After our prepared remarks, we will open the call to Q&A. To ask a question, please click the raise hand feature in the webinar portal. As a reminder, various remarks that we make during this presentation about the company's future expectatio ...